semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Heart Failure Advanced chronic heart failure (HF) will be defined as left ventricular ejection fraction less than 35%, creatinine less than 2 mg/dL, and CHF NY functional class III-IV for more than 3 months. Enrolled patients should be admitted to hospital due to heart failure requiring adjustment of inotropic agents or diuretics within recent 6 months  presence of mitral stenosis or prosthetic mitral valve 2. any abnormality of atrial septum (e.g., atrial septal defect or aneurysm) 3. inadequate image quality 4. lack of informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Hypercholesterolemia Men, 40-65 yrs/old, postmenopausal women 50-65 yrs/old not > 5 yrs post menopause. All subjects were hypercholesterolemic with either total cholesterol >240 mg/dl and < 320 mg/dL or LDL cholesterol >140 mg/dl and <190 mg/dl at the screening visit  Excluded subjects included diabetics, people being actively treated with niacins, fibrates, statins, insulin, ACE inhibitors or other cholesterol/ blood pressure pharmaceutical treatments, people who consumed large amounts of soy, flax, rye breads, pumpkin seeds, hydrolyzed milk products, sterols, and/or berries (strawberries/blueberries) or supplements aimed at cholesterol reduction such as spruce lignans, sytrinol (poly methoxylated flavanols), polycosinols, people consuming flaxseed on a regular basis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stable Angina Hypertension Stable angina I-III class by the Canadian Cardiovascular Society Classification and concomitant primary hypertension Subject is on beta-blockers treatment for at least 2 months prior to into survey, with no dose change for a minimum of 4 weeks  Use of phenylalkylamine and benzothiazepine calcium channel blockers Hemodynamic significant mitral and aortic valve disease Acute myocardial infarction and unstable angina within 3 months before enrolment
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Diabetes Mellitus Cardiomyopathy written informed consent no disease history BNP level within the normal range Normal renal function (serum creatinine of more than 1.3 mg/dL and/or creatinin clearance greater than 80ml/min) Normal ECG  systolic blood pressure < 90 mmHg subjects on any medication abnormal glucose metabolism history of anaphylaxis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Coronary Disease Hypercholesterolemia Patients who have been diagnosed as stable angina pectoris, and successful percutaneous coronary intervention (PCI) were performed with intravascular ultrasound (IVUS) and optical coherence tomography (OCT) guidance. 2. Patients having coronary plaques (≧ 500 µm in thickness or % plaque of 20% or more at ≧ 5 mm distal or proximal to the previously treated area in the same branch of coronary artery. 3. Patients with dyslipidemia as defined by any of the following TC ≧ 220 mg/dL LDL-C ≧ 140 mg/dL Cholesterol-lowering treatment is allowed according to the investigator's judgment when LDL-C ≧ 100 mg/dL or TC ≧ 180mg/dL Patients who are under cholesterol-lowering treatment and LDL-C ≦ 120 mg/dL 4. Patients 20 years or older at the time of their consent. 5. Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial  Patients with bypass graft or in-stent restenosis at the site of PCI. 2. Patients who received PCI in the past on the lesion where the evaluation of coronary plaque volume is planned. 3. Patients who had plaques in a non-culprit site and might receive PCI during the treatment period. 4. Patients receiving lipid-lowering drugs (fibrates, probucol, nicotinic acid, cholestyramine or cholesterol absorption inhibitors). 5. Patients with familial hypercholesterolemia. 6. Patients with cardiogenic shock. 7. Patients receiving cyclosporine. 8. Patients with any allergy to pravastatin and rosuvastatin. 9. Patients with hepatobiliary disorders. 10. Pregnant women, women suspected of being pregnant, or lactating women. 11. Patients with renal disorders (Cr≧2.0mg/dL) or undergoing dialysis. 12. Patients who are ineligible in the opinion of the investigator
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetes Mellitus Oxidative Stress Male or female with age 18-80 years Type 2 diabetes mellitus On stable dose of metformin (more than 1000mg) for at least 1 month HbA1c 7~10% Subjects on statins, ACE inhibitors, ARBs and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study BP under control no change required to BP medications Agreement to maintain prior diet & exercise  Type 1 DM or Any kind of secondary DM Pregnant or lactating women Treatment with sulfonylurea, α-glucosidase inhibitor, glinide, GLP-1 analogues, DPP-IV inhibitors or insulin therapy within 1 month prior to informed consent Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent HbA1c <7% or >10% Uncontrolled hypertension ( BP > 160/100 mmHg) Congestive heart failure (NYHA class I to IV)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiomyopathy Chest Pain Dyspnea Ischemic cardiomyopathy patients on optimal medical treatment. Optimal medical treatment is defined as the continued symptoms of chest pain or dyspnea despite treatment with 2 antiischemic agents (beta blockers, CCB or nitrates). Unless contraindicated, all cardiomyopathy patients should be treated with a beta blocker and an ACEI/ARB. 2. Anginal chest pain or dyspnea 3. Documentation of non treatable or optimally treated coronary artery disease 4. Ejection Fraction of less than or equal to 40%  Less than 18 years of age 2. Pregnant or breast feeding 3. Patients with non ischemic cardiomyopathy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 15.0-70.0,  Transfusion Related Complications patients who sign the consent, with Glasgow Coma Scale (GCS) score of 15, undergoing surgery which blood loss could be more than 800ml or 20% of the patient's whole blood volume  Pregnancy Psychopathy Refuse to sign consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 34.0-69.0,  Diabetes Mellitus Vitamin D Deficiency Type 2 diabetes mellitus Hgb A1c greater then 7.0 Adults aged 34 to 69 years  known primary hyperparathyroidism, sarcoidosis, tuberculosis, cancer, potential terminal illness history of serum creatinine more than 2.0 mg/dL vitamin D supplement more than 200 IU/day history of inflammatory bowel disease, hypercalcemia or kidney stones
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Dyspnea Pulmonary Disease Patients presenting with shortness of breath secondary or not to heart failure, even with cardiac shock and LVAD Patients with valvular disease chronic stable heart failure post partum Cardiomyopathy  terminal cancer progressive neurological disease pregnancy opposition of the patient
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Hypertension Diabetes Mellitus, Type 2 Albuminuria type 2 diabetes with stable controlled (HbA1c between 6.5-10%) SBP between 130-180mmHg or DBP between 80-110mmHg microalbuminuria (UAE 30-300mg/24hrs or creatinine 30-300mg/g)  IDDM or secondary forms of diabetes hepatic and/or renal dysfunction serum potassium level > 5.5mmol/L severe renal disease Chronic Heart Failure (NYHA class III or IV) unstable CV disease PTCA within 3 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Over the age of 18 years 2. In sinus rhythm at the time of randomisation 3. Have a LVEF <0.45 and a left ventricular end-diastolic dimension >60 mm or >34 mm/m2 4. Are receiving ACE inhibitor, β-blocker and diuretic therapy at the optimal doses. 5. Has been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation. 6. Documented, stable heart failure. Must have at least 1 of the following Hospitalised with a discharge diagnosed of heart failure in the last 6 months Evidence of pulmonary congestion on chest X-ray Evidence of heart failure on echocardiogram Evidence of heart failure on ECG 7. Willing and able to provide informed consent  Systolic BP >160mmHg or <90mmHg 2. Diastolic BP >95mmHg 3. Uncorrected primary valvular disease 4. Active myocarditis 5. Obstructive or restrictive Cardiomyopathy 6. Exercise capacity limited by other factors not including dyspnoea 7. Myocardial infarction within the previous 6 months 8. Stroke within the previous 12 months 9. Hospitalisation within one month of randomisation 10. A history of supraventricular arrhythmia or sustained ventricular arrhythmia 11. Claudication 12. Severe primary pulmonary (VC <1.5L), renal or hepatic disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 4.0-16.0,  Type 1 Diabetes The are: Diagnosis of type I diabetes for at least two years prior to enrollment, the ability tolerate wearing the continuous blood glucose monitoring device for a total of 6 days, and the ability to follow a prescribed meal plan  The are: Medical conditions that could potentially affect the absorption of nutrients such as celiac disease of inflammatory bowel disease and the use of any fiber supplements at home
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 4.0-80.0,  GNE Myopathy GNE Related Diseases Age 4-80 years, either gender, inclusive. 2. Diagnosis of GNE myopathy or GNE-related diseases based upon the identification of GNE gene mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study. 3. Subjects that are a carrier family member of a patient on the study are eligible to participate. 4. Must be able to provide informed consent  Psychiatric illness or other diseases that would interfere with the subject s ability to comply with the requirements of this protocol. 2. Hepatic laboratory parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) or renal laboratory parameters (creatinine, blood urea nitrogen [BUN]) greater than 3 times the upper limit of normal. 3. Presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease not related to the primary disease process
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Type-2 Diabetes Mellitus Ischemic Heart Disease type-2 diabetes coronary artery disease  age >80 years acute coronary syndrome life expectancy <1 year unable to give informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes Mellitus, Type 1 Participant is willing and able to give informed consent for participation in the study Male or Female, aged between 18 and 65 years Diagnosed with Type 1 Diabetes Mellitus (T1DM) HbA1c < 10% or 86 mmol/mol Treated with a basal bolus regimen using either insulin glargine or insulin detemir as the basal insulin Exercising regularly for at least 1 hour per week on average  People with any one of the following complications of diabetes stage 2+ diabetic retinopathy renal impairment (with creatinine >150micromol/l) known history or symptoms of cardiovascular disease foot ulceration peripheral vascular disease Pregnancy or breastfeeding Untreated or unstable respiratory disease Known hypoglycaemia unawareness Treatment with drugs known to interfere with glucose metabolism